We screened a panel of epigenetic inhibitors targeting histone H3 methyltransferase and demethylases and assessed anti-tumorigenic effects of these epigenetic probes on ovarian cancer cells with MECOM amplification. Here, MBD2 is linked to ovarian cancer.